Bharat Biotech's nasal vaccine gets nod of regulator for phase 2/3 trial
Published By : Prameya News Bureau | August 13, 2021 IST
Share
New Delhi, August 13: Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for phase 2/3 trials. This is the first of its kind COVID-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. BBIL has in-licensed technology from Washington University in St Louis, USA. Phase 1 clinical trial has been completed in age groups ranging ≥18 to ≤60 years. The company reports that the doses of the vaccine administered to healthy volunteers in the phase I clinical trial, has been well tolerated. No serious adverse events reported. Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit high level of neutralizing antibodies in animal studies. The regulatory approval has been received for conducting “A Phase 2 randomized, multi-centric, Clinical Trial of Heterologus Prime-Boost Combination of SARS-CoV-2 Vaccines to evaluate the immunogenicity and safety of BBV152 (COVAXIN®) with BBV154 (Adenoviral Intranasal COVID-19 vaccine) in healthy volunteers.” Dr Renu Swarup, Secretary, DBT and Chairperson, BIRAC speaking on the subject said that Bharat Biotech’s BBV154 Covid Vaccine is the first intranasal vaccine being developed in the country entering into late-stage clinical trials.
News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
Virat Kohli's statue installed at Jaipur Wax Museum on World Heritage Day
Punjab electoral officer to go Live for election-related queries
Jilted lover stabs corporator's daughter to death in Karnataka college campus
Nestle baby food sugar study causes concern in India, Nestle India's shares fall
'Yamraj' files nomination as Independent for Maharashtra's Madha LS seat
ED reveals Kejriwal's high glycaemic index diet plan, AAP alleges political vendetta
Suprme Court reserves verdict on pleas seeking mandatory EVM-VVPAT tally
LS poll: BJP nominates Narayan Rane from Ratnagiri Sindhudurg
ED attaches Shilpa Shetty and Raj Kundra's assets worth Rs 98 Cr
FIR filed against woman accusing Ravi Kishan is father of her daughter
Kashi sculptor's replica of Ram Lalla idol for Netherlands Temple
Lok Sabha polls: More rallies, roadshows planned for PM Modi in UP
Over 25 Million voters set to cast ballots in Rajasthan's first phase of Lok Sabha Elections
Political controversy erupts over attack on youths chanting 'Jai Shri Ram' in Bengaluru
Odisha-Chhattisgarh border on high alert after Kanker encounter
ECoR to run 40 Summer Special trains
Boys born to mothers with HIV more vulnerable to death in infancy
'Their govt is for 20-25 select people...', Rahul Gandhi's jibe at BJP in Karnataka rally
Bihar man shot dead by terrorists in J&K's Anantnag
Campaign ends for first phase of LS polls in Assam